Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joakim Ramsberg

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Lakartidningen|November 8, 2007
[Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions]Ulf Persson, Joakim Ramsberg
The New England Journal of Medicine|April 21, 2016
Challenges for Sharing Data from Embedded ResearchRichard Platt, Joakim Ramsberg
Health Economics|September 25, 2007
On survival consumption costs: a reply to NymanDouglas Lundin, Joakim Ramsberg
Learning Health Systems|June 28, 2019
Opportunities and barriers for pragmatic embedded trials: Triumphs and tribulationsJoakim Ramsberg, Richard Platt
Plos One|August 10, 2012
Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelJoakim Ramsberg, Christian Asseburg, Martin Henriksson
Lakartidningen|February 24, 2006
[Why patent-protected drugs' cost efficiency should be compared with generic preparations]Fredrik Berggren, Douglas Lundin, Joakim Ramsberg
BMJ Open|January 7, 2012
A cost-effectiveness analysis of an in-hospital clinical pharmacist serviceSusanna M Wallerstedt, Lina Bladh, Joakim Ramsberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first yearJoakim Ramsberg, Stefan Odeberg, Andreas Engström, et al.
Health Policy (Amsterdam, Netherlands)|March 17, 2015
Patient perspectives on centralisation of low volume, highly specialised procedures in SwedenIda Svederud, Martin Virhage, Emma Medin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluationLinus Jönsson, Rickard Sandin, Mattias Ekman, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Lakartidningen|November 8, 2007
[Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions]Ulf Persson, Joakim Ramsberg
The New England Journal of Medicine|April 21, 2016
Challenges for Sharing Data from Embedded ResearchRichard Platt, Joakim Ramsberg
Health Economics|September 25, 2007
On survival consumption costs: a reply to NymanDouglas Lundin, Joakim Ramsberg
Learning Health Systems|June 28, 2019
Opportunities and barriers for pragmatic embedded trials: Triumphs and tribulationsJoakim Ramsberg, Richard Platt
Plos One|August 10, 2012
Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelJoakim Ramsberg, Christian Asseburg, Martin Henriksson
Lakartidningen|February 24, 2006
[Why patent-protected drugs' cost efficiency should be compared with generic preparations]Fredrik Berggren, Douglas Lundin, Joakim Ramsberg
BMJ Open|January 7, 2012
A cost-effectiveness analysis of an in-hospital clinical pharmacist serviceSusanna M Wallerstedt, Lina Bladh, Joakim Ramsberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first yearJoakim Ramsberg, Stefan Odeberg, Andreas Engström, et al.
Health Policy (Amsterdam, Netherlands)|March 17, 2015
Patient perspectives on centralisation of low volume, highly specialised procedures in SwedenIda Svederud, Martin Virhage, Emma Medin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluationLinus Jönsson, Rickard Sandin, Mattias Ekman, et al.
Pageof 2